Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases.

Cancers (Basel) · 2026 · PMC12896431 · PMID 41681994

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significancep = 0.076so close (0.05 < p ≤ 0.1)

Median OS was not reached in the major/complete response group, whereas it was 46.1 months (95% CI 32.4–59.8) in the no/minor response group; however, this difference did not reach statistical significance ( p = 0.076; Figure 3 A).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.